| Primary information |
|---|
| ID | antitb_1283 |
| Peptide Name | Inhibitor 12 |
| Sequence | W-(boroMet) |
| N-terminal Modification | Addition of N-(2-(3,5-Difluorophenyl)acetyl) |
| C-terminal Modification | Free |
| Chemical Modification | boroMet = methionine boronic acid |
| Linear/ Cyclic | Linear |
| Length | 2 |
| Chirality | L |
| Nature | NA |
| Source | Synthetic |
| Origin | substrate-based boronate inhibitors |
| Species | Mycobacterium tuberculosis |
| Strain | Mycobacterium tuberculosis H37Rv |
| Inhibition Concentartion | MIC50 = 12 μM |
| In vitro/In vivo | In vitro |
| Cell Line | Myeloma cells (MM1.S) |
| Inhibition Concentartion | NA |
| Cytotoxicity | No cytotoxicty |
| In vivo Model | None |
| Lethal Dose | NA |
| Immune Response | NA |
| Mechanism of Action | Inhibit ClpP1P2 peptidase activity and protein degradation in the presence of ClpC1 and ClpX ATPases. |
| Target | ClpP1P2 peptidase |
| Combination Therapy | None |
| Other Activities | None |
| Pubmed ID | 25759383 |
| Year of Publication | 2015 |
| 3-D Structure | NA |